http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015512409-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-02 |
| filingDate | 2013-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2015512409-A |
| titleOfInvention | 4-Aminopyridine as a therapeutic agent for spinal muscular atrophy |
| abstract | Pharmacological blockade of K + channels (use of FDA-approved broad spectrum K + channel blocker 4-AP) occurs with excitatory disturbances in motor circuits due to interneuron or sensory neuron input, a significant consequence of SMN depletion It was found to be definitely beneficial to the smn mutant phenotype. Based on these observations, certain embodiments of the present invention can include one or more potassium channels such as 4-aminopyridine, 4- (dimethylamino) pyridine, 4- (methylamino) pyridine and 4- (aminomethyl) pyridine. It is directed to a method of treating SMA by administering a therapeutically effective amount of a blocking agent. Another aspect is directed to a new pharmaceutical formulation comprising two or more potassium channel blockers. [Selection] Figure 7D |
| priorityDate | 2012-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 121.